Exact Mass: 230.1419

Exact Mass Matches: 230.1419

Found 54 metabolites which its exact mass value is equals to given mass value 230.1419, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

Camoensine

Oprea1_574945

C14H18N2O (230.1419)


   

Ibudilast

2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one

C14H18N2O (230.1419)


Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DC - Leukotriene receptor antagonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Propyphenazone

1,5-dimethyl-2-phenyl-4-(propan-2-yl)-2,3-dihydro-1H-pyrazol-3-one

C14H18N2O (230.1419)


N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BB - Pyrazolones C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

5,6-Dehydroalbine

5,6-Dehydroalbine

C14H18N2O (230.1419)


   

11alpha-Allylcytisine

11alpha-Allylcytisine

C14H18N2O (230.1419)


   

Propyphenazone

4-Isopropylantipyrine

C14H18N2O (230.1419)


N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BB - Pyrazolones C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents CONFIDENCE standard compound; INTERNAL_ID 2653 CONFIDENCE standard compound; INTERNAL_ID 2272 CONFIDENCE standard compound; INTERNAL_ID 8550

   

1,2-Dimethyl-6-methoxy-1,2,3,4-tetrahydro-beta-carboline

1,2-Dimethyl-6-methoxy-1,2,3,4-tetrahydro-beta-carboline

C14H18N2O (230.1419)


   

Alkaloid PA-I

Alkaloid PA-I

C14H18N2O (230.1419)


   

1-propyl-2,3,4,9-tetrahydro-1H-beta-carbolin-6-ol|1-Propyl-6-hydroxy-1,2,3,4-tetrahydro-2-carboline|1-Propyl-6-hydroxyl-1,2,3,4-tetrahydro-beta-carboline|schobericine|schobicine

1-propyl-2,3,4,9-tetrahydro-1H-beta-carbolin-6-ol|1-Propyl-6-hydroxy-1,2,3,4-tetrahydro-2-carboline|1-Propyl-6-hydroxyl-1,2,3,4-tetrahydro-beta-carboline|schobericine|schobicine

C14H18N2O (230.1419)


   

4-allyl-1,2,5,6,11,11a-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-10-one|Dehydro-albin|Dehydroalbin

4-allyl-1,2,5,6,11,11a-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-10-one|Dehydro-albin|Dehydroalbin

C14H18N2O (230.1419)


   

Propyphenazon

Propyphenazone

C14H18N2O (230.1419)


N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BB - Pyrazolones C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics CONFIDENCE standard compound; INTERNAL_ID 4071 D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

Tabernanthalog

Tabernanthalog

C14H18N2O (230.1419)


   

Ketas

2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one

C14H18N2O (230.1419)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DC - Leukotriene receptor antagonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

5-(diethylaminomethyl)quinolin-8-ol

5-(diethylaminomethyl)quinolin-8-ol

C14H18N2O (230.1419)


   

1-(1H-Indol-3-ylmethyl)-4-piperidinol

1-(1H-Indol-3-ylmethyl)-4-piperidinol

C14H18N2O (230.1419)


   

1-(1H-Indol-3-ylmethyl)-3-piperidinol

1-(1H-Indol-3-ylmethyl)-3-piperidinol

C14H18N2O (230.1419)


   

4-(1H-INDOL-6-YL)-1-METHYL-PIPERIDIN-4-OL

4-(1H-INDOL-6-YL)-1-METHYL-PIPERIDIN-4-OL

C14H18N2O (230.1419)


   

N-[4-(DIMETHYLAMINO)BENZYL]-N-(2-FURYLMETHYL)AMINE

N-[4-(DIMETHYLAMINO)BENZYL]-N-(2-FURYLMETHYL)AMINE

C14H18N2O (230.1419)


   

2-BENZYLOXYMETHYL-4-ISOPROPYL-1H-IMIDAZOLE

2-BENZYLOXYMETHYL-4-ISOPROPYL-1H-IMIDAZOLE

C14H18N2O (230.1419)


   

7-(PIPERIDIN-4-YL)-3,4-DIHYDROQUINOLIN-2(1H)-ONE

7-(PIPERIDIN-4-YL)-3,4-DIHYDROQUINOLIN-2(1H)-ONE

C14H18N2O (230.1419)


   

1-Piperidineacetonitrile,a-(4-methoxyphenyl)-

1-Piperidineacetonitrile,a-(4-methoxyphenyl)-

C14H18N2O (230.1419)


   
   

4-phenyl-2,8-diazaspiro[4.5]decan-3-one

4-phenyl-2,8-diazaspiro[4.5]decan-3-one

C14H18N2O (230.1419)


   

4-Hydroxy-1-phenethyl-piperidine-4-carbonitrile

4-Hydroxy-1-phenethyl-piperidine-4-carbonitrile

C14H18N2O (230.1419)


   

2-(4-tert-butylphenyl)-5-methyl-4H-pyrazol-3-one

2-(4-tert-butylphenyl)-5-methyl-4H-pyrazol-3-one

C14H18N2O (230.1419)


   

5-Methoxy-3-piperidin-4-yl-1H-indole

5-Methoxy-3-piperidin-4-yl-1H-indole

C14H18N2O (230.1419)


   

5-(4-METHYL-PIPERAZIN-1-YL)-INDAN-1-ONE

5-(4-METHYL-PIPERAZIN-1-YL)-INDAN-1-ONE

C14H18N2O (230.1419)


   

1-Benzyl-1,7-diazaspiro[4.4]nonan-6-one

1-Benzyl-1,7-diazaspiro[4.4]nonan-6-one

C14H18N2O (230.1419)


   

3-(PYRROLIDIN-1-YLCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE

3-(PYRROLIDIN-1-YLCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE

C14H18N2O (230.1419)


   

1-Benzyl-4-(Hydroxymethyl)piperidine-4-carbonitrile

1-Benzyl-4-(Hydroxymethyl)piperidine-4-carbonitrile

C14H18N2O (230.1419)


   

(1H-Indol-3-ylmethyl)-(tetrahydro-furan-2-ylmethyl)-amine

(1H-Indol-3-ylmethyl)-(tetrahydro-furan-2-ylmethyl)-amine

C14H18N2O (230.1419)


   

7-BENZYL-2,7-DIAZASPIRO[4.4]NONAN-3-ONE

7-BENZYL-2,7-DIAZASPIRO[4.4]NONAN-3-ONE

C14H18N2O (230.1419)


   

2,8-Diazaspiro[4.5]decan-1-one,2-phenyl-

2,8-Diazaspiro[4.5]decan-1-one,2-phenyl-

C14H18N2O (230.1419)


   

6-piperidin-1-yl-3,4-dihydro-2H-isoquinolin-1-one

6-piperidin-1-yl-3,4-dihydro-2H-isoquinolin-1-one

C14H18N2O (230.1419)


   

4-(1H-INDOL-5-YL)-1-METHYL-PIPERIDIN-4-OL

4-(1H-INDOL-5-YL)-1-METHYL-PIPERIDIN-4-OL

C14H18N2O (230.1419)


   

3-benzyl-3,6-diazabicyclo[3.2.2]nonan-7-one

3-benzyl-3,6-diazabicyclo[3.2.2]nonan-7-one

C14H18N2O (230.1419)


   

BRL-54443

3-(1-methylpiperidin-4-yl)-1H-indol-5-ol

C14H18N2O (230.1419)


BRL 54443 is a potent 5-HT1E/1F receptor agonist (Ki values are 1.1 nM and 0.7 nM respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors[1].

   

9-Benzyl-3,9-diaza-bicyclo[4.2.1]nonan-4-one

9-Benzyl-3,9-diaza-bicyclo[4.2.1]nonan-4-one

C14H18N2O (230.1419)


   

4-Piperidinecarbonitrile,4-(3-methoxyphenyl)-1-methyl-

4-Piperidinecarbonitrile,4-(3-methoxyphenyl)-1-methyl-

C14H18N2O (230.1419)


   

N,N-Diallyl-3-aminoacetanilide

N,N-Diallyl-3-aminoacetanilide

C14H18N2O (230.1419)


   

7-Methoxy-2,5-dimethyl-1,2,3,4-tetrahydropyrimido[3,4-a]-indole

7-Methoxy-2,5-dimethyl-1,2,3,4-tetrahydropyrimido[3,4-a]-indole

C14H18N2O (230.1419)


   

Ibudilast

Ibudilast

C14H18N2O (230.1419)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DC - Leukotriene receptor antagonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

(2E)-2-(3,3-Dimethyl-2,4-dihydroisoquinolin-1-ylidene)-N-methylacetamide

(2E)-2-(3,3-Dimethyl-2,4-dihydroisoquinolin-1-ylidene)-N-methylacetamide

C14H18N2O (230.1419)


   

NA-Tryptamine 4:0

NA-Tryptamine 4:0

C14H18N2O (230.1419)


   

(1r,9r,10s)-7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

(1r,9r,10s)-7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

C14H18N2O (230.1419)


   

(1r,9s,10r)-7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

(1r,9s,10r)-7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

C14H18N2O (230.1419)


   

(1s,9r,12r)-12-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,5-dien-4-one

(1s,9r,12r)-12-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,5-dien-4-one

C14H18N2O (230.1419)


   

(1s,9s,10r)-10-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,4-dien-6-one

(1s,9s,10r)-10-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,4-dien-6-one

C14H18N2O (230.1419)


   

7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

C14H18N2O (230.1419)


   

12-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,5-dien-4-one

12-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,5-dien-4-one

C14H18N2O (230.1419)


   

(1r,9r,10r)-7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

(1r,9r,10r)-7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

C14H18N2O (230.1419)


   

(1s,9s,12r)-12-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,5-dien-4-one

(1s,9s,12r)-12-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,5-dien-4-one

C14H18N2O (230.1419)


   

(1s,9s,10s)-7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

(1s,9s,10s)-7,14-diazatetracyclo[7.6.1.0²,⁷.0¹⁰,¹⁴]hexadeca-2,4-dien-6-one

C14H18N2O (230.1419)


   

10-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,4-dien-6-one

10-(prop-2-en-1-yl)-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,4-dien-6-one

C14H18N2O (230.1419)